PEAQX

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PEAQX
PEAQX.png
Systematic (IUPAC) name
({[(1S)-1-(4-bromophenyl)ethyl]amino}-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl)phosphonic acid
Clinical data
Legal status
?
Identifiers
ATC code ?
Synonyms PEAQX, NVP-AAM077
Chemical data
Formula C17H17BrN3O5P 
Mol. mass 454.211 g/mol
 YesY (what is this?)  (verify)

PEAQX is a competitive antagonist at the NMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies[1] of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent anticonvulsant in animal tests.[2]


References[edit]

  1. ^ Frizelle PA, Chen PE, Wyllie DJ Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. Molecular Pharmacology 2006 Sep;70(3):1022-32. PMID 16778008
  2. ^ Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorganic and Medicinal Chemistry Letters. 2002 Apr 8;12(7):1099-102. PMID 11909726